Virtual Diabetes Prevention Program—Effects on Medicare Advantage Health Care Costs and Utilization

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 45-LB
Author(s):  
VINAY CHIGULURI ◽  
DOUGLAS BARTHOLD ◽  
RAJIV GUMPINA ◽  
CYNTHIA CASTRO SWEET ◽  
JASON PIERATT ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Prevention Program ◽  
Diabetes Prevention ◽  
Diabetes Prevention Program ◽  
Medicare Advantage ◽  
Program Effects ◽  
Care Costs

Health Care Utilization and Medical Cost Outcomes from a Digital Diabetes Prevention Program in a Medicare Advantage Population

2020 ◽  
Vol 23 (6) ◽  
pp. 414-421
Author(s):  
Douglas Barthold ◽  
Vinay Chiguluri ◽  
Rajiv Gumpina ◽  
Cynthia Castro Sweet ◽  
Jason Pieratt ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Medical Cost ◽  
Prevention Program ◽  
Diabetes Prevention ◽  
Diabetes Prevention Program ◽  
Care Utilization ◽  
Medicare Advantage ◽  
Cost Outcomes

899-P: Barriers and Facilitators to Implementation of the Group-Based Diabetes Prevention Program within a Large Health-Care System

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 899-P
Author(s):  
MEGHAN HALLEY ◽  
CATHERINE NASRALLAH ◽  
NINA K. SZWERINSKI ◽  
JOHN P. PETERSEN ◽  
ROBERT J. ROMANELLI ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care System ◽  
Prevention Program ◽  
Diabetes Prevention ◽  
Diabetes Prevention Program ◽  
Barriers And Facilitators ◽  
Large Health Care System ◽  
Care System

Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Alpesh Amin ◽  
Allison Keshishian ◽  
Lin Xie ◽  
Onur Baser ◽  
Kwanza Price ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Major Bleeding ◽  
Bleeding Event ◽  
Bleeding Risk ◽  
Medical Costs ◽  
Medicare Advantage ◽  
Major Bleeding Event ◽  
Treatment Naïve ◽  
Care Costs

Objective: The study aim was to compare major bleeding risk and health care costs after initiating oral anticoagulants (OACs) for treatment-naïve non-valvular atrial fibrillation (NVAF) patients. Methods: Patients in the Medicare advantage population prescribed apixaban, rivaroxaban, dabigatran or warfarin were selected from the Optum Research Database 01JAN2013-31DEC2014. The first OAC prescription date was designated as the index date. Patients were required to have a NVAF diagnosis, continuous health plan enrollment for 6 months and no OAC claims before the index date. Patients were classified into four cohorts based on their index OAC prescription. Major bleeding events, identified by the Cunningham algorithm plus additional bleeding sites, were compared using a Cox proportional hazards model. Health care costs were calculated per patient per month and compared using generalized linear models. Results: The study included 36,260 patients: 3,762 apixaban, 2,677 dabigatran, 8,740 rivaroxaban, and 21,081 warfarin patients. CHA2DS2-VASc score was higher in apixaban patients (4.2) compared to dabigatran and rivaroxaban (both 4.0; p<0.001), but lower than in warfarin patients (4.3; p<0.001). After adjusting for baseline characteristics, apixaban patients were significantly less likely to have a major-bleeding event within one year of treatment initiation compared to rivaroxaban (HR=0.69; 95% CI=0.59-0.81) and warfarin (HR=0.71; 95% CI=0.61-0.82) patients and trended towards numerically lower major bleeding compared to dabigatran patients (HR=0.87; 95% CI=0.72-1.06). Major bleeding-related medical costs were lower in apixaban patients ($53) compared to rivaroxaban ($111) and warfarin ($138) patients (p<0.001) and similar to dabigatran patients ($44, p=0.370). Furthermore, apixaban patients incurred lower all-cause medical costs ($1,646) compared to dabigatran ($1,974, p=0.02), rivaroxaban ($1,909, p=0.002) and warfarin ($2,162, p<0.001) patients. Conclusion: In a large national Medicare advantage population, treatment-naïve NVAF patients treated with apixaban were significantly less likely to have a major-bleeding event compared to those prescribed rivaroxaban or warfarin and had significantly lower medical costs.

scholarly journals Heterogeneity of health care costs among medicare advantage patients with type 1 diabetes

2014 ◽  
Vol 17 (3) ◽  
pp. A246
Author(s):  
G.S. Clore ◽  
S.L. Slabaugh ◽  
B.H. Curtis ◽  
H. Fu ◽  
D.P. Schuster
Keyword(s):  
Health Care ◽  
Type 1 Diabetes ◽  
Health Care Costs ◽  
Medicare Advantage ◽  
Care Costs

scholarly journals Effect on Health Care Expenditures During Nationwide Implementation of the Diabetes Prevention Program as a Health Insurance Benefit

Diabetes Care ◽  
2019 ◽  
Vol 42 (9) ◽  
pp. 1776-1783 ◽  
Author(s):  
Ronald T. Ackermann ◽  
Raymond Kang ◽  
Andrew J. Cooper ◽  
David T. Liss ◽  
Ann M. Holmes ◽  
...  
Keyword(s):  
Health Care ◽  
Health Insurance ◽  
Prevention Program ◽  
Diabetes Prevention ◽  
Diabetes Prevention Program ◽  
Health Care Expenditures ◽  
Insurance Benefit ◽  
Nationwide Implementation

What are the health care costs for chronic lymphocytic leukemia?

2017 ◽  
Vol 35 (8_suppl) ◽  
pp. 15-15 ◽  
Author(s):  
Matthew J. Matasar ◽  
Stacey DaCosta Byfield ◽  
Cori Blauer-Peterson ◽  
Melissa Montez ◽  
Carolina Reyes ◽  
...  
Keyword(s):  
Health Care ◽  
Chronic Lymphocytic Leukemia ◽  
Health Care Costs ◽  
Fixed Number ◽  
Lymphocytic Leukemia ◽  
New Drugs ◽  
Patient Treatment ◽  
Medicare Advantage ◽  
Care Costs

15 Background: New drugs for chronic lymphocytic leukemia (CLL) have recently been approved, including oral therapies. We examined total health care costs, including drug and patient out-of-pocket (OOP) costs, in patients (pts) initiating CLL treatment. Methods: This retrospective studyused a U.S. health insurance claims database. Adult commercially insured and Medicare Advantage pts from 5/2013 - 6/2015, with ≥2 medical claims for CLL were included. Pts required ≥1 claim for NCCN-recommended systemic cancer therapy. Pts were categorized based on first-line of therapy. Aggregate costs during a fixed 9-month follow-up period (treatment switch or discontinuation were possible) were investigated. Mean and standard deviation (SD) of total healthcare costs, regimen costs, and pt OOP regimen costs are presented. Results: A total of 707 CLL pts met all study criteria during the study period; 40% were commercially insured and 60% had Medicare Advantage. Mean age was 70 years (SD 11). Some of the most common regimens received included Bendamustine+Rituximab (BR) (N=186), Ibrutinib (Ibr) (N=101), Fludarabine, Cyclophosphamide, and Rituximab (FCR) (N=62), and Obinutuzumab +/- Chlorambucil (Ob+/-Chl) (N=51). Mean length of therapy varied by regimen; BR 4.2 months (m) (SD 2.7), Ibr 6.7m (SD 4.8), FCR 4.7m (SD 2.1), and Ob±Chl 4.0m (SD 2.1). The table shows aggregate costs among pts with ≥ 9 months follow-up. Ob±Chl had lower costs compared to other cohorts. Ibr had the highest drug costs. Conclusions: While the study has limited follow-up, Ob+/-Cl had the lowest drug and total costs. Oral therapy with Ibr had the highest drug and OOP costs compared to those associated with a prescribed fixed number of cycles. The magnitude of the difference between orals and infusions is expected to be greater with a longer follow-up and is a consideration in patient treatment decision-making in CLL.[Table: see text]

scholarly journals Lessons from Launching the Diabetes Prevention Program in a Large Integrated Health Care Delivery System: A Case Study

2017 ◽  
Vol 20 (4) ◽  
pp. 262-270 ◽  
Author(s):  
Colin D. Rehm ◽  
Melinda E. Marquez ◽  
Elizabeth Spurrell-Huss ◽  
Nicole Hollingsworth ◽  
Amanda S. Parsons
Keyword(s):  
Health Care ◽  
Delivery System ◽  
Health Care Delivery ◽  
Prevention Program ◽  
Diabetes Prevention ◽  
Care Delivery ◽  
Diabetes Prevention Program ◽  
Health Care Delivery System ◽  
System A

scholarly journals Secondary Impact of Social Media via Text Message Screening for Type 2 Diabetes Risk in Kuwait: Survey Study

JMIR Diabetes ◽  
10.2196/20532 ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e20532
Author(s):  
Naeema Alqabandi ◽  
Ebaa Al-Ozairi ◽  
Adel Ahmed ◽  
Edgar L Ross ◽  
Robert N Jamison
Keyword(s):  
Type 2 Diabetes ◽  
Health Care ◽  
At Risk ◽  
Social Media ◽  
Prevention Program ◽  
Text Messaging ◽  
Diabetes Prevention ◽  
Text Message ◽  
Diabetes Prevention Program

Background Type 2 diabetes mellitus (T2DM) is an international problem of alarming epidemic proportions. T2DM can develop due to multiple factors, and it usually begins with prediabetes. Fortunately, this disease can be prevented by following a healthy lifestyle. However, many health care systems fail to properly educate the public on disease prevention and to offer support in embracing behavioral interventions to prevent diabetes. SMS messaging has been combined with cost-effective ways to reach out to the population at risk for medical comorbidities. To our knowledge, the use of nationwide SMS messaging in the Middle East as a screening tool to identify individuals who might be at risk of developing T2DM has not been reported in the literature. Objective The primary aim of this study was to assess the feasibility of conducting a series of SMS messaging campaigns directed at random smartphone users in Kuwait for the detection and prevention of T2DM. It was predicted that 1% of those receiving the text message would find it relevant and participate in the study. The secondary aim of this study was to assess the incidence of participation of those who were forwarded the initial text message by family members and friends. Methods In this study, 5 separate text message screening campaigns were launched inviting recipients to answer 6 questions to determine the risk of developing T2DM. If subjects agreed to participate, a link to the prediabetes screening test devised by the Centers for Disease Control and Prevention was automatically transmitted to their mobile devices. Those identified as high risk were invited to participate in a diabetes prevention program. Results A total of 180,000 SMSs were sent to approximately 6% of the adult population in Kuwait. Of these, 0.14% (260/180,000) of the individuals who received the SMS agreed to participate, of whom 58.8% (153/260) completed the screening. Surprisingly, additional surveys were completed by 367 individuals who were invited via circulated SMS messages forwarded by family members and friends. Altogether, 23.3% (121/520) qualified and agreed to participate in a diabetes prevention program. The majority of those who chose to participate in the prevention program were overweight, aged 45-65 years, and reported being less physically active than those who chose not to participate (χ22=42.1, P<.001). Conclusions Although health care screening via text messaging was found to have limited effectiveness by itself, it exhibited increased reach through shared second-party social media messaging. Despite the fact a subpopulation at possible risk of developing T2DM could be reached via text messaging, most responders were informed about the screening campaign by family and friends. Future research should be designed to tap into the benefits of social media use in health risk campaigns.

Sign in / Sign up

Export Citation Format

Share Document